Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 17 Mar 2024
Reviewer's report:
I read with interest the paper by  Na et al. It is an interesting retrospective study comparing the
effectiveness of anti-TNFs and ustekinumab in patients with Crohn's Disease.
There is an important limitation not disclosed in the manuscript: the authors did not provide
results in terms of endoscopic and biochemical (in particular,  fecal calprotectin levels)
remission.
Since mucosal healing is the target of biological therapy in IBD, all the studies should be thought
with this endpoint. If not, the significance of the study  is limited and should be clearly indicated
in discussion section.
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 17 Mar 2024
Reviewer's report:
I read with interest the paper by  Na et al. It is an interesting retrospective study comparing the
effectiveness of anti-TNFs and ustekinumab in patients with Crohn's Disease.
There is an important limitation not disclosed in the manuscript: the authors did not provide
results in terms of endoscopic and biochemical (in particular,  fecal calprotectin levels)
remission.
Since mucosal healing is the target of biological therapy in IBD, all the studies should be thought
with this endpoint. If not, the significance of the study  is limited and should be clearly indicated
in discussion section.
Please review this paper.
user
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 1 Date: 17 Mar 2024
Reviewer's report:
I read with interest the paper by  Na et al. It is an interesting retrospective study comparing the
effectiveness of anti-TNFs and ustekinumab in patients with Crohn's Disease.
There is an important limitation not disclosed in the manuscript: the authors did not provide
results in terms of endoscopic and biochemical (in particular,  fecal calprotectin levels)
remission.
Since mucosal healing is the target of biological therapy in IBD, all the studies should be thought
with this endpoint. If not, the significance of the study  is limited and should be clearly indicated
in discussion section.
assistant